Clinical Trial Update: BP1001-A in Patients With Advanced or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update states that BP1001-A is being evaluated in a Phase 1 study for advanced or recurrent solid tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• BP1001-A (antisense oligonucleotide targeting Bcl-2)

Snippet

Sponsor: Bio-Path Holdings, Inc. | Conditions: Solid Tumor, Adult, Carcinoma, Ovarian Epithelial | Phase 1 | Status: RECRUITING